Drug Profile
Estradiol valerate/dienogest - Bayer Schering Pharma
Alternative Names: BAY 865027; Dienogest/estradiol valerate - Bayer Schering Pharma; DUB Qlaira; DUB-OC; E2/DNG - Bayer Schering Pharma; Natazia; Qlaira; SH T00658; SH T00658ID; SH T00658K; SH T00658LLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
- Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Metrorrhagia; Pregnancy
Most Recent Events
- 16 Apr 2021 Discontinued - Phase-III for Metrorrhagia in China, Thailand, Taiwan (PO)
- 01 Jun 2015 Bayer completes a phase III trial in Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (NCT01638923)
- 02 Mar 2015 Estradiol valerate/dienogest is still in a phase III trial for Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (PO)